Siolta Therapeutics Inc.
San Carlos, CA
- UEI
- L35PX15HHJQ7
- CAGE
- 80CV3
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 930 Brittan Ave, San Carlos, CA 94070, USA
- Website
- sioltatherapeutics.com
- Founded
- 2016
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Osel, Inc. | Mountain View, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Unlocked Labs Inc. | Laramie, WY | — |
| Fzata Inc. | Halethorpe, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Vedanta Biosciences, Inc. | Cambridge, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Topaz Biosciences, Inc. | Emeryville, CA | — |
About the company
Siolta Therapeutics Inc. is a biotechnology company located in San Carlos, California, focused on developing live biotherapeutic products (LBPs) that leverage microbiome science to prevent and treat various medical conditions. Registered in SAM.gov since December 2017, the company is a for-profit corporate entity specializing in developing innovative bacterial-based therapeutic solutions targeting specific health challenges across multiple medical domains, with a particular emphasis on pediatric and women's health conditions.
The company has secured multiple project grants from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program, totaling over $829,498 in federal funding. These grants support the development of three distinct live biotherapeutic products: STMC-105 for preventing recurrent bacterial vaginosis in women, STMC-106 for preventing and treating necrotizing enterocolitis in preterm infants, and STMC-103H for preventing allergic diseases in children. Each project involves sophisticated microbiome research, focusing on selecting and combining specific bacterial strains to address complex medical conditions. The research involves systematic strain selection, developing co-culture conditions, formulating mucoadhesive delivery methods, and conducting in vitro and in vivo testing to evaluate the therapeutic potential of these innovative bacterial products. The ultimate goals of these projects include creating FDA-approvable live biotherapeutic products that can durably restore protective microbiota, reduce opportunistic pathogens, and improve clinical outcomes across different patient populations.
Quick answers
Is Siolta Therapeutics Inc. registered in SAM.gov?
Yes. Siolta Therapeutics Inc.'s SAM.gov registration is active through March 31, 2027.
What is Siolta Therapeutics Inc.'s most recent federal award?
Siolta Therapeutics Inc.'s most recent federal grant award is Development of a multispecies live biotherapeutic product for the prevention of recurrent bacterial vaginosis (R44AI195248), from National Institute of Allergy and Infectious Diseases (NIH), on August 5, 2025.
On GovTribe
See Siolta Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors